Nicolas Girard

NEJM — Zongertinib eerste-lijns bij HER2-gemuteerd gevorderd NSCLC: 76% respons

The New England journal of medicine · 15 april 2026

Ifinatamab Deruxtecan in Patiënten met Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Fase II IDeate...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 februari 2026

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Gevorderd NSCLC: A Gerandomiseerde, Double-Blind, E...

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 1 november 2025

Totale overleving with Amivantamab-Lazertinib in EGFR-Mutated Gevorderd NSCLC.

The New England journal of medicine · 30 oktober 2025

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Gevorderd NSCLC: The COC...

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 1 oktober 2025

Totale overleving with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.

The New England journal of medicine · 21 augustus 2025

Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.

The New England journal of medicine · 19 juni 2025

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 april 2025

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Gevorderd or Metastatic Non-Small Cell Lung Cancer: Th...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 januari 2025

Amivantamab plus lazertinib als eerstelijns bij EGFR-gemuteerd NSCLC: MARIPOSA fase III definitief

The New England journal of medicine · 24 oktober 2024

Sotorasib 960 mg of 240 mg bij KRAS G12C NSCLC

European journal of cancer (Oxford, England : 1990) · 1 september 2024

Sacituzumab govitecan versus docetaxel bij eerder behandeld NSCLC: EVOKE-01 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 augustus 2024

Nivolumab plus chemotherapie bij EGFR-gemuteerd NSCLC na TKI: CheckMate 722 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 april 2024

Amivantamab plus chemotherapie bij EGFR exon 20 inserties NSCLC: PAPILLON fase III

The New England journal of medicine · 30 november 2023

CT plus röntgen versus röntgen alleen bij follow-up van gereseceerd NSCLC: gerandomiseerde studie

The Lancet. Oncology · 1 september 2022

Neoadjuvant nivolumab plus chemotherapie bij resectabel longcarcinoom: CheckMate 816 fase III

The New England journal of medicine · 26 mei 2022

Emibetuzumab plus erlotinib versus erlotinib bij gevorderd NSCLC: fase II

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 1 januari 2020